Post-Ozempic patients may eat more calories, Deutsche Bank survey finds

Buyers have cheered a brand new class of weight reduction medication for his or her skill to assist individuals shed undesirable kilos, however the findings of a latest ballot underscore the challenges sufferers face in the event that they stop therapy.

The survey by Deutsche Financial institution discovered that calorie consumption declines when a affected person takes a GLP-1 medicine like Novo Nordisk’s Ozempic or Wegovy. Nonetheless, as soon as the medicine is stopped, the variety of energy a affected person consumes will rise once more — and in some instances, will probably be even increased than what she or he was consuming earlier than therapy started, the survey discovered.

The polling was performed in December, and concerned 600 U.S. customers, Deutsche Financial institution stated in a analysis be aware. Seventy % of the individuals have been utilizing a GLP-1 drug when questioned, whereas the remaining 30% had stopped taking this kind of medicine. The funding financial institution performed the survey as a part of its makes an attempt to higher perceive the long-term implications of anti-obesity medicines, which additionally embrace Eli Lilly’s Zepbound, on the meals and beverage trade.

The survey discovered that among the many sufferers nonetheless on medicine, about 30% stated they ate “rather less,” whereas 22% stated they ate a “lots much less.”

“Maybe surprisingly, 17% of respondents said that they have been consuming much more and 18% a bit extra,” the financial institution’s analysts wrote. “This meant {that a} web 18% of those that have been utilizing GLP-1 medicine have been consuming much less.”

“Nonetheless, amongst those that have been now not taking GLP-1 this greater than reversed with a web 30% stating that they have been now consuming greater than they have been previous to utilizing GLP-1 medicine,” the report stated.

“We imagine that the survey conclusions again up our view that GLP-1 is just not a cause in of itself to keep away from investing in Meals and Beverage shares,” the analysts wrote within the be aware.

Definitely, 2023 was a 12 months value forgetting for a lot of meals and beverage shares, with many underperforming the market. For these shares that managed to eke out a acquire in 2023, the upside probably got here late within the 12 months.

Many meals and beverage shares started falling in the summertime, as consciousness of GLP-1 medicines like Wegovy unfold. The transfer accelerated after the discharge of information from Novo Nordisk in August confirmed that the medication might assist sufferers not solely drop extra pounds but in addition enhance their cardiovascular well being. Buyers began to fret that individuals would broadly undertake the medication and there could be all kinds of ripple results, which began to be mirrored in inventory costs.

However within the midst of the market’s year-end rally, a contemporary batch of information additionally confirmed that sufferers who took Zepbound and stopped regained round half the burden that they had misplaced whereas they have been on the therapy. That discovering helped a number of the affected shares to get better.

Shares of Mondelez, the maker of Oreos and Cadbury, gained 16% over the previous three months, which helped it tally an 8% acquire over the previous 12 months. Kraft Heinz shares posted a ten.2% loss over the previous 12 months, however has reaped a 19% acquire over the three-month interval. U.S.-traded shares of Nestle are up greater than 5% over the previous three months, however the inventory has a 2% loss over the previous 12 months. Unilever shares comply with the same sample. Shares of the Ben & Jerry’s proprietor are up practically 2% over the previous three months, however are down greater than 3% over the previous 12 months.

Deutsche Financial institution stated the affect of anti-obesity medicines on meals and beverage shares must assessed “within the context of all weight reduction packages and the chance that GLP-1 cannibalises such packages, limiting the online impact on meals and beverage producers.”

Dr. Shantanu Gaur, founder and CEO of Allurion Applied sciences, stated the outcomes of the survey are usually not shocking. Allurion, which went public through SPAC in August, is growing a gastric balloon and habits modification packages to deal with weight problems.

“That is one thing that you’d count on,” he stated explaining that “urge for food can return with a vengeance” as soon as sufferers cease GLP-1 remedy. Our bodies have a tendency to hunt out a “set level,” or a most well-liked weight mass the place they’ll return to with out intervention and habits modification.

Semaglutide, the energetic ingredient in Ozempic and Wegovy, acts like a pure hormone, glucagon-like peptide-1, or GLP-1, within the physique to manage insulin ranges within the blood and suppress urge for food. Zepbound (tirzepatide) mimics GLP-1 in addition to a second incretin, glucose-dependent insulinotropic polypeptide, or GIP. As soon as these hormones are now not supplemented within the physique, starvation alerts will return.

The American Medical Affiliation has stated that weight problems is a power situation, and Novo Nordisk and Eli Lilly count on sufferers who take incretin medicines will must be on the medication long run to manage their weight. On this approach, incretin medication are like medicines which can be taken for situations corresponding to hypertension and ldl cholesterol. Sufferers aren’t instructed to cease taking these medication as soon as their blood strain and levels of cholesterol fall to a wholesome vary. In the event that they do, the readings are prone to spike once more.

However even with blood strain medicine, compliance will be a problem. Dr. Gaur stated about half of individuals on ldl cholesterol medicine will cease taking it after a 12 months. The speed of compliance is even decrease with anti-obesity medicines, he stated.

In the meantime, Deutsche Financial institution stated it expects curiosity in weight reduction packages could also be peaking as proven by web search information, and that tends to be a great time for buyers to carry meals and beverage shares. Nestle and Unilever are the agency’s prime European picks, whereas Mondelez and Kraft rank amongst its favored U.S. staples names.

“The principle level is that utilization of GLP-1 medication is not only a pure addition to the overall variety of individuals on weight reduction packages, it’s a part of your entire eco-system,” the report stated. “We suspect that lots of the solutions given with regard to consumption could be comparable for these given by many individuals after they begin a weight reduction program.”

Do not miss these tales from CNBC PRO: